Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
Total Valuation
Cardiol Therapeutics has a market cap or net worth of $147.00M. The enterprise value is C$116.45M.
Market Cap$147.00M
Enterprise ValueC$116.45M
Share Statistics
Cardiol Therapeutics has 99,997,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99,997,650
Owned by Insiders3.78%
Owned by Institutions4.27%
Financial Efficiency
Cardiol Therapeutics’s return on equity (ROE) is -1.48 and return on invested capital (ROIC) is -161.62%.
Return on Equity (ROE)-1.48
Return on Assets (ROA)-1.15
Return on Invested Capital (ROIC)-161.62%
Return on Capital Employed (ROCE)-1.62
Revenue Per Employee0.00
Profits Per Employee-2.04M
Employee Count18
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cardiol Therapeutics is ―. Cardiol Therapeutics’s PEG ratio is -0.23.
PE Ratio―
PS Ratio0.00
PB Ratio5.35
Price to Fair Value5.35
Price to FCF-5.28
Price to Operating Cash Flow-4.88
PEG Ratio-0.23
Income Statement
In the last 12 months, Cardiol Therapeutics had revenue of 0.00 and earned -36.68M in profits. Earnings per share was -0.51.
Revenue0.00
Gross Profit-373.11K
Operating Income-40.28M
Pretax Income-36.68M
Net Income-36.68M
EBITDA-36.30M
Earnings Per Share (EPS)-0.51
Cash Flow
In the last 12 months, operating cash flow was -24.22M and capital expenditures -27.55K, giving a free cash flow of -24.25M billion.
Operating Cash Flow-24.22M
Free Cash Flow-24.25M
Free Cash Flow per Share-0.24
Dividends & Yields
Cardiol Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.29
52-Week Price Change-28.21%
50-Day Moving Average1.48
200-Day Moving Average1.59
Relative Strength Index (RSI)46.70
Average Volume (3m)136.50K
Important Dates
Cardiol Therapeutics upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Cardiol Therapeutics as a current ratio of 4.52, with Debt / Equity ratio of 1.21%
Current Ratio4.52
Quick Ratio4.52
Debt to Market Cap<0.01
Net Debt to EBITDA0.84
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cardiol Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cardiol Therapeutics EV to EBITDA ratio is -2.81, with an EV/FCF ratio of -4.07.
EV to Sales0.00
EV to EBITDA-2.81
EV to Free Cash Flow-4.07
EV to Operating Cash Flow-4.07
Balance Sheet
Cardiol Therapeutics has $11.62M in cash and marketable securities with $134.20K in debt, giving a net cash position of $11.49M billion.
Cash & Marketable Securities$11.62M
Total Debt$134.20K
Net Cash$11.49M
Net Cash Per Share$0.11
Tangible Book Value Per Share$0.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cardiol Therapeutics is $10.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.57
Price Target Upside654.84% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast21.17%